Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at 40 weeks compared to placebo, meeting the study's main goal. Patients started the trial with an A1c in the range of 7% to 9.5%, and were not taking other diabetes medications. Retatrutide ...

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tabpatent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an over ...

Novo Nordisk is targeting Japanese patients willing to pay out-of-pocket for GLP-1 drugs such as Wegovy https://t.co/NQyHCefLpD ...

Core Insights - The pharmaceutical giant is re-entering the obesity market with the goal of becoming a top-three player, competing with Eli Lilly and Novo Nordisk [1] Group 1 - The company aims to establish a significant presence in the obesity treatment sector, indicating a strategic shift in its market focus [1] - The re-entry into the obesity market suggests a response to growing demand for effective weight management solutions [1] - The competitive landscape includes established players like Eli Lilly and Novo Nordisk, highlighting the challenges the company may face in gaining market share [1]

Core Insights - Evotec has received a $10 million milestone payment from Bristol Myers Squibb (BMS) for the initiation of a Phase 1 clinical study of BMS-986506, a novel treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer [1][2] - This clinical study marks a significant advancement in the strategic collaboration between Evotec and BMS, focusing on protein degradation and the development of molecular glue candidates [2][3] Group 1: Clinical Development - The dosing of the first patient in the Phase 1 clinical trial signifies the transition of Evotec-BMS oncology platform into clinical evaluation [1][2] - BMS-986506 is a cereblon E3 ligase modulator developed under the strategic partnership, which aims to create new treatment paradigms in oncology [1][3] Group 2: Collaboration and Technology - The collaboration combines Evotec's PanOmics and PanHunter platforms with BMS's library of CELMoDs, aiming to identify novel molecular glue degraders for high-value oncology targets [3][6] - Evotec's drug discovery platform utilizes high-performance multi-omics screening and AI-enabled data analytics to selectively target and eliminate disease-driving proteins [2][7] Group 3: Molecular Glue Technology - Molecular glue degraders represent a new class of therapeutics that can induce interactions between E3 ubiquitin ligases and target proteins, leading to their degradation [5][6] - This mechanism significantly expands the range of druggable proteins, addressing the limitations of conventional small molecule therapeutics [4][5]

Core Viewpoint - Johnson & Johnson (J&J) has transitioned by spinning off its consumer health business to focus on innovative medicine and medtech, despite facing challenges from the loss of exclusivity of its top-selling drug, Stelara [1][2] Group 1: Company Performance - J&J has shown resilience by managing growth in its two main businesses despite the decline of Stelara [2] - The company's shares have increased by 15% this year, contrasting with the S&P 500's decline, indicating strong performance during uncertain market conditions [4] - J&J has 28 platforms or products generating at least $1 billion annually, allowing it to move past the Stelara exclusivity loss [5] Group 2: Financial Metrics - J&J's market capitalization is $572 billion, with a current share price range between $235.50 and $239.11 [6] - The company has a gross margin of 67.97% and a dividend yield of 2.19% [6] Group 3: Dividend Growth - J&J is recognized as a Dividend King, having increased its dividend for over 50 years, demonstrating a commitment to shareholder returns [7] - The company pays a dividend of $5.20, which is higher than the S&P 500's dividend yield of 1.1%, making it an attractive option for passive income [9]

The companies developing new weight-loss medicines have a problem: the balance of power has shifted, and patients are bailing out of their clinical trials https://t.co/BocxOcXt5i ...

An employee has been awarded workers’ compensation benefits after being injured when performing a “common courtesy” even though her employer maintains what she did was outside the course and scope of her employment.The Virginia Workers’ Compensation Commission (VWCC) has affirmed benefits for an Abbott Laboratories employee who suffered a cervical spine injury at the company’s national sales conference when she attempted to move her manager’s heavy backpack to another table where she and her team colleagues ...

Group 1 - AstraZeneca plans to establish a cell therapy manufacturing and supply base along with an innovation center in Shanghai, aiming to be the first global drugmaker with comprehensive cell therapy capabilities in China [1][2] - The new facility will focus on the production and supply of autologous CART cell therapies for China and other Asian markets [2]

RT Tehran Times (@TehranTimes79)#BREAKINGTajikistan sent pharmaceutical, medical, hygiene, food and construction materials aid to Iran https://t.co/VSgbOPFKOX ...